Altimmune Profit Margin

Altimmune (ALT) currently reports a profit margin of -296000.0% as of June 2026. That compares with -438730.0% in the prior-year period — up 32.5% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Altimmune's profit margin history and peer comparisons.

Altimmune's profit margin increased from -438730.0% to -296000.0% — a 32.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Altimmune's profit margin of -296000.0% is lower than the Healthcare sector average of 13.89%. That is roughly 2131105.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Altimmune's current -296000.0% should be judged against Healthcare norms (sector average: 13.89%) and against ALT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -296000.0%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Altimmune, and consider following ALT for alerts when major investors trade the stock.